Medprin Regenerative Medical Technologies Co. Ltd. (301033) — Net Asset Momentum
Medprin Regenerative Medical Technologies Co. Ltd. (301033) recorded a net asset momentum of 10.0% as of December 2024, with net assets of CN¥699.66 Million CNY. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See 301033 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
YoY Momentum
Current Net Assets
Years of Data
Country
Medprin Regenerative Medical Technologies Co. Ltd. Net Asset Momentum (2019–2024)
This chart tracks Medprin Regenerative Medical Technologies Co. Ltd.'s year-over-year net asset growth across 6 annual reporting periods from 2019 to 2024. The most recent momentum reading is +10.0%, with net assets of CN¥699.66 Million CNY as of December 2024. Read 301033 total liabilities for a breakdown of total debt and financial obligations.
Annual Net Asset History for Medprin Regenerative Medical Technologies Co. Ltd. (2019–2024)
The table below shows the complete annual net asset history for Medprin Regenerative Medical Technologies Co. Ltd. from 2019 to 2024, covering 6 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and broader valuation context, see 301033 market cap.
| Year | Net Assets (CNY) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2024 | CN¥699.66 Million | CN¥799.23 Million | CN¥99.57 Million | ▲ +10.0% |
| 2023 | CN¥635.86 Million | CN¥786.97 Million | CN¥151.11 Million | ▲ +5.5% |
| 2022 | CN¥602.58 Million | CN¥744.92 Million | CN¥142.34 Million | ▲ +4.6% |
| 2021 | CN¥575.87 Million | CN¥746.78 Million | CN¥170.92 Million | ▲ +70.3% |
| 2020 | CN¥338.07 Million | CN¥455.34 Million | CN¥117.26 Million | ▲ +11.7% |
| 2019 | CN¥302.78 Million | CN¥340.05 Million | CN¥37.27 Million | — |